Insights J Clin Psychiatry September 2026

Population Pharmacokinetics and Dosing Simulations for Paliperidone Palmitate 351 mg as Alternative Maintenance Doses in Patients With Schizophrenia or Schizoaffective Disorder

JCP 2026;87(4):10.4088/JCP.26m16416

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. Clinical Summary Some patients with schizophrenia or schizoaffective disorder remain symptomatic on the highest approved monthly paliperidone palmitate dose, while others want longer intervals between injections without losing maintenance exposure. This analysis addresses both problems by modeling whether LY03010 351 mg can approximate either intensified monthly treatment or less frequent maintenance schedules. FAQ What did this study find about paliperidone palmitate 351 mg every 4 weeks for patients who need more exposure than standard monthly dosing?

Key Takeaways The population pharmacokinetic model was built from 5,731 plasma paliperidone concentrations in 276 subjects and showed good agreement between simulated and observed 5th, 50th, and 95th percentiles, supporting the credibility of the exposure comparisons used for these off-label scenarios. Clinical Guide How should clinicians consider LY03010 351 mg every 4 weeks for patients with schizophrenia or schizoaffective disorder who have an inadequate response to standard monthly paliperidone palmitate? Clinical Guide How should clinicians choose between LY03010 351 mg every 6 weeks and every 8 weeks when planning extended-interval maintenance treatment for schizophrenia or schizoaffective disorder?